

Zyprexa Business Processes

Zyprexa Key Decision Team

- Purpose: Efficient, cross-representational critical decision-making body for the Zyprexa Product Team
- Types of Decisions: Clinical study priorities, label changes / modifications, publication priorities, key issues management, key marketplace decisions, IPP final submission, Zyprexa Marketing Plan
- Chair: Alan Breier
- Voting Members:
 - Alan Breier, Product Team Leader
 - Vin Rampey, Operations
 - Mauricio Tohen, Team Medical
 - Denice Torres, Marketing
 - Jack Jordan, U.S. Affiliate
 - Paula Trapez, U.S. Affiliate* Voting members may send a surrogate as back-up
- Other attendees: Based on subject matter
- Other roles:
 - Agenda development and outcome communication – Denice Torres
 - Scheduling and minutes – Alice Finch
- Freq. of meetings: Once a month standing meeting (one hour), other meetings scheduled on the basis of need
- Process: Decisions topics submitted to Alan Breier, as soon as practical (ideally within 72 hours of meeting). Ad hoc urgent situation meetings, please try and give 48 hours notice if possible

Voting members will be given notice of a decision-making meeting by voice mail and e-mail.

Decision made on the basis of a group vote. (Alan Breier retains the right to make a final decision if he is opposed to the group vote.)

It is preferred that voting members participate in all meeting (by presence or phone) if possible. Voting

members may cast their vote if they are not present, by informing another voting team member or sending a surrogate.

Minutes and decisions are sent out to the voting team within 48 hours of the meeting.

Classification of
Decisions:

Final Decision
Preliminary position pending additional information
No decision but agreement on critical steps

**Zyprexa Product Team
Key Decision Team**

Subject:

Action Requested:

Decision Required:

Timing for Making the Decision:

Key Assumptions Surround the Decision: